Evidence map›Paper›PMID 32538844›Full record

Observational studyJournal of Alzheimer's disease : JAD2020

Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative.

Mackenzie E Fowler, Kristen L Triebel, Gary R Cutter, Lon S Schneider, Richard E Kennedy, Alzheimer’s Disease Neuroimaging Initiative

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mackenzie E FowlerDepartment of Epidemiology, University of Alabama, Birmingham, Birmingham, AL, USA.
Kristen L TriebelDivision of Neuropsychology, Department of Neurology, University of Alabama, Birmingham, Birmingham, AL, USA.
Gary R CutterDepartment of Biostatistics, University of Alabama, Birmingham, Birmingham, AL, USA.
Lon S SchneiderUniversity of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Richard E KennedyDivision of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama, Birmingham, Birmingham, AL, USA.
Alzheimer’s Disease Neuroimaging Initiative
University of Alabama at Birmingham · USUniversity of Southern California · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.R01AG057684 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KENNEDY, RICHARD E, SCHNEIDER, LON S · 2017 to 2021
$3.2M
Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and ImproveR01AG037561 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHNEIDER, LON S · 2011 to 2013
$1.6M
CIHRNIA NIH HHS P30 AG066530NIA NIH HHS R01 AG037561NIA NIH HHS R01 AG057684NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundCross-sectional studies suggest self-reported cancer history is associated with decreased risk of Alzheimer's disease (AD). However, little is known about how self-reported cancer affects longitudinal AD progression, the primary outcome in clinical trials and observational studies.

objectiveTo determine self-reported cancer history's effect on longitudinal AD progression in an observational study.

methodsWe utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to evaluate progression to AD by self-reported all-cancer, breast, prostate, colorectal, or non-melanoma skin cancer history. Linear mixed effects models were used to examine baseline differences and rates of progression on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) by self-reported cancer history. Age at AD onset was examined using consensus clinical diagnoses with Cox proportional hazards regression.

resultsAmong 1,271 participants, models revealed no significant differences in progression over time but did reveal significantly lower baseline ADAS-Cog score, indicating better cognition at a given age in those with self-reported cancer history. Cox models indicated those with self-reported cancer history had significantly later age of AD onset (HR: 0.67, 95% CI: 0.53-0.85) after adjustment for covariates.

conclusionParticipants with self-reported cancer history entered ADNI with better cognition and later age of AD onset, but progressed similarly to participants without such history, indicating differences in AD between those with and without self-reported cancer history emerge early in the disease course. Such differences in longitudinal progression by self-reported cancer history could affect AD trials and observational studies, given the current focus on early disease course. Further investigation is warranted with detailed longitudinal assessment of cancer and AD.

Indexed as

Disease ProgressionSelf ReportAgedAged, 80 and overAlzheimer DiseaseFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasmsNeuroimagingAlzheimer’s diseasecancercognitive impairmentdisease progressionmild cognitive impairment

Identifiers

PMID32538844
PMCPMC7928167
OpenAlexW3035561911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.